- Home
- NTIP vs DYAI Comparison
NTIP vs DYAI Comparison
Compare NTIP & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NTIP | DYAI |
|---|---|---|
| Founded | 1990 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.4M | 32.5M |
| IPO Year | 2013 | 2003 |
Fundamental Metrics
Financial Performance| Metric | NTIP | DYAI |
|---|---|---|
| Price | $1.57 | $0.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 16.2K | ★ 173.2K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | ★ 7.30% | N/A |
| EPS Growth | ★ 15.38 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $150,000.00 | ★ $3,090,345.00 |
| Revenue This Year | N/A | $122.79 |
| Revenue Next Year | N/A | $100.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 50.00 | N/A |
| 52 Week Low | $1.24 | $0.48 |
| 52 Week High | $1.75 | $1.60 |
Technical Indicators
Market Signals| Indicator | NTIP | DYAI |
|---|---|---|
| Relative Strength Index (RSI) | 56.55 | 25.74 |
| Support Level | $1.46 | N/A |
| Resistance Level | $1.66 | $0.90 |
| Average True Range (ATR) | 0.05 | 0.06 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 77.70 | 10.05 |
Price Performance
Historical ComparisonAbout NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.
About DYAI Dyadic International Inc.
Dyadic International Inc is a biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.